COMP <GO>
ADMA vs LLY // EV/EBITDA & P/E VALUATION
ADMA Biologics Inc (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ADMA 4
— LLY 9
▲ EV/EBITDA & P/E VALUATION LEADER: ADMA
LAST: $11.75 (+4.17%) • MKT CAP: $2.63B
valuation
12.4x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | 83.64% | -26.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | 32.36% | +0.54 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.4x | 36.4x | -24.02 | ADMA | /valuation <GO> |
| Free Cash Flow Yield | 1.06% | 2.30% | -1.24 | LLY | /fcf-yield <GO> |
| Operating Margin | 37.50% | 40.21% | -2.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 28.80% | 31.90% | -3.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 45.51% | -25.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.98 | 9.29 | +3.69 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.1 | 66.6 | -2.52 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | 26.3x | -11.25 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.63B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | LLY REV | ADMA GROSS % | LLY GROSS % | ADMA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $65.18B | 57.4% | 83.0% | $27.8M | $16.81B |
| FY 2024 | $426.5M | $45.04B | 51.5% | 81.3% | $110.4M | $8.82B |
| FY 2023 | $258.2M | $34.12B | — | 79.3% | $8.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
LLY // BETA 0.51